Exendin-4 alleviates high glucose-induced rat mesangial cell dysfunction through the ampk pathway

Cellular Physiology and Biochemistry

Volumn 33, Issue 2, 2014, Pages 423-432

  Xu, Wen Wei ^a   Guan, Mei Ping ^a   Zheng, Zong Ji ^a   Gao, Fang ^a   Zeng, Yan Mei ^a   Qin, Yan ^a   Xue, Yao Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; Cell proliferation; ERK; Fibronectin; MMP 2; mTOR; TIMP 2

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; EXENDIN 4; FIBRONECTIN; GELATINASE A; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; BETA CATENIN; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; MESANGIUM CELL; MTT ASSAY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; WESTERN BLOTTING; CELL DAMAGE; CYTOKINE RELEASE; DOSE RESPONSE; DOWN REGULATION; EXTRACELLULAR MATRIX; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; UPREGULATION;

MAMMALIA; RATTUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL PROLIFERATION; DIABETIC NEPHROPATHIES; GENE EXPRESSION REGULATION; GLUCOSE; HYPOGLYCEMIC AGENTS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 2; MESANGIAL CELLS; PEPTIDES; RATS; SWEETENING AGENTS; TOR SERINE-THREONINE KINASES; VENOMS;

EID: 84895573645     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358623     Document Type: Article

References (39)

1. De Zeeuw D, Parving HH, Henning RH: Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17:2100-2105.
2. Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16:S30-33.
3. Caenazzo C, Garbisa S, Onisto M, Zampieri M, Baggio B, Gambaro G: Effect of glucose and heparin on mesangial alpha 1(IV)COLL and MMP-2/TIMP-2 mRNA expression. Nephrol Dial Transplant 1997;12:443-448.
4. Tan RJ, Liu Y: Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol 2012;302:F1351-1361.
5. Catania JM, Chen G, Parrish AR: Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007;292:F905-911.
6. Hopps E, Caimi G: Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med 2012;23:99-104.
7. Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC, Sam F: Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc 2013;2:e005868.
8. Tency I, Verstraelen H, Kroes I, Holtappels G, Verhasselt B, Vaneechoutte M, Verhelst R, Temmerman M: Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor. PLoS One 2012;7:e49042.
9. Dai B, Cui M, Zhu M, Su WL, Qiu MC, Zhang H: STAT1/3 and ERK1/2 Synergistically Regulate Cardiac Fibrosis Induced by High Glucose. Cell Physiol Biochem 2013;32:960-971.
10. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta 2007;1773:1299-1310.
11. Wan-Xin T, Tian-Lei C, Ben W, Wei-Hua W, Ping F: Effect of mitofusin 2 overexpression on the proliferation and apoptosis of high-glucose-induced rat glomerular mesangial cells. J Nephrol 2012;25:1023-1030.
12. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, Nagamatsu T: Advanced-glycation-end-product-cholesterol-Aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Eur J Pharmacol 2011;672:159-168.
13. Heilig CW, Deb DK, Abdul A, Riaz H, James LR, Salameh J, Nahman NS, Jr.: GLUT1 regulation of the pro-sclerotic mediators of diabetic nephropathy. Am J Nephrol 2013;38:39-49.
14. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978.
15. Li W, Cui M, Wei Y, Kong X, Tang L, Xu D: Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem 2012;30:749-757.
16. Lindegaard B, Matthews VB, Brandt C, Hojman P, Allen TL, Estevez E, Watt MJ, Bruce CR, Mortensen OH, Syberg S, Rudnicka C, Abildgaard J, Pilegaard H, Hidalgo J, Ditlevsen S, Alsted TJ, Madsen AN, Pedersen BK, Febbraio MA: Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes 2013;62:3064-3074.
17. Samson SL, Sathyanarayana P, Jogi M, Gonzalez EV, Gutierrez A, Krishnamurthy R, Muthupillai R, Chan L, Bajaj M: Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-Alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. Diabetologia 2011;54:3093-3100.
18. Kim MY, Lim JH, Youn HH, Hong YA, Yang KS, Park HS, Chung S, Ko SH, Shin SJ, Choi BS, Kim HW, Kim YS, Lee JH, Chang YS, Park CW: Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1alpha axis in db/db mice. Diabetologia 2013;56:204-217.
19. Filippatos TD, Elisaf MS: Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013;4:190-201.
20. Ojima A, Ishibashi Y, Matsui T, Maeda S, Nishino Y, Takeuchi M, Fukami K, Yamagishi S: Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013;182:132-141.
21. Lee J, Hong SW, Chae SW, Kim DH, Choi JH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY: Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012;7:e31394.
22. Almilaji A, Munoz C, Elvira B, Fajol A, Pakladok T, Honisch S, Shumilina E, Lang F, Foller M: AMP-Activated protein kinase regulates hERG potassium channel. Pflugers Arch 2013;465:1573-1582.
23. Bhavsar SK, Schmidt S, Bobbala D, Nurbaeva MK, Hosseinzadeh Z, Merches K, Fajol A, Wilmes J, Lang F: AMPKalpha1-sensitivity of Orai1 and Ca2+ entry in T-lymphocytes. Cell Physiol Biochem 2013;32:687-698.
24. Seo-Mayer PW, Thulin G, Zhang L, Alves DS, Ardito T, Kashgarian M, Caplan MJ: Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol 2011;301:F1346-1357.
25. Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y, Lee SX, Ou Y, Asara JM, Cantley LC, Zheng B: Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation. Mol Cell 2013;10.1016/j. molcel.2013.08.044
26. Xu J, Ji J, Yan XH: Cross-Talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr 2012;52:373-381.
27. Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL: The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. Peptides 2013;39:71-79.
28. O'Neill LA, Hardie DG: Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346-355.
29. Salminen A, Hyttinen JM, Kaarniranta K: AMP-Activated protein kinase inhibits NF-kappaB signaling and inflammation: Impact on healthspan and lifespan. J Mol Med (Berl) 2011;89:667-676.
30. Couser WG: Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998;13 Suppl 1:10-15.
31. Kurogi Y: Mesangial cell proliferation inhibitors for the treatment of proliferative glomerular disease. Med Res Rev 2003;23:15-31.
32. Kanwar YS, Sun L, Xie P, Liu FY, Chen S: A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423.
33. Inada A, Nagai K, Arai H, Miyazaki J, Nomura K, Kanamori H, Toyokuni S, Yamada Y, Bonner-Weir S, Weir GC, Fukatsu A, Seino Y: Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol 2005;167:327-336.
34. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE: Decreased matrix degradation in diabetic nephropathy: Effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002;45:268-275.
35. Del Prete D, Anglani F, Forino M, Ceol M, Fioretto P, Nosadini R, Baggio B, Gambaro G: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997;40:1449-1454.
36. Ebihara I, Nakamura T, Shimada N, Koide H: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-550.
37. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573.
38. Han SY, Jee YH, Han KH, Kang YS, Kim HK, Han JY, Kim YS, Cha DR: An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006;21:2406-2416.
39. Rysz J, Banach M, Stolarek RA, Pasnik J, Cialkowska-Rysz A, Koktysz R, Piechota M, Baj Z: Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 2007;20:444-452.